Predictions
Aptose Biosciences
Start price
Target price
Perf. (%)
€4.64
01.05.21
01.05.21
€4.50
01.05.22
01.05.22
-30.60%
11.06.21
11.06.21
Could be worthwhile Investment >10% per year
Organigram Holdings Inc.
Start price
Target price
Perf. (%)
€8.92
26.04.21
26.04.21
-
26.04.22
26.04.22
-38.92%
08.02.22
08.02.22
Oncolytics Biotech
Start price
Target price
Perf. (%)
€2.42
18.04.21
18.04.21
€4.00
18.04.22
18.04.22
-33.47%
20.12.21
20.12.21
Aptose Biosciences
Start price
Target price
Perf. (%)
€5.50
24.03.21
24.03.21
€5.50
24.03.22
24.03.22
-15.64%
01.05.21
01.05.21
Could be worthwhile Investment >10% per year
Organigram Holdings Inc.
Start price
Target price
Perf. (%)
€13.28
12.03.21
12.03.21
€24.00
12.03.22
12.03.22
-62.26%
12.03.22
12.03.22
Could be very worthwhile Investment >20% year
Organigram Holdings Inc.
Start price
Target price
Perf. (%)
€10.48
25.02.21
25.02.21
-
25.02.22
25.02.22
-18.82%
04.05.21
04.05.21
Organigram Holdings Inc.
Start price
Target price
Perf. (%)
€10.93
22.02.21
22.02.21
€100.00
22.02.22
22.02.22
-36.55%
12.12.21
12.12.21
Organigram Holdings Inc.
Start price
Target price
Perf. (%)
€14.40
09.02.21
09.02.21
€28.00
09.02.22
09.02.22
-59.94%
10.02.22
10.02.22
Organigram Holdings Inc.
Start price
Target price
Perf. (%)
€10.48
08.02.21
08.02.21
€14.00
08.02.22
08.02.22
-53.66%
28.01.22
28.01.22
Organigram Holdings Inc.
Start price
Target price
Perf. (%)
€5.88
25.01.21
25.01.21
€16.00
25.01.22
25.01.22
-15.72%
26.01.22
26.01.22
Aurinia Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€11.99
15.01.21
15.01.21
-
4.50%
05.02.21
05.02.21
Risky Investment
Arbutus Biopharma Corp.
Start price
Target price
Perf. (%)
€2.75
19.11.20
19.11.20
€2.90
19.11.21
19.11.21
-11.05%
10.07.21
10.07.21
Differentiated customer and product portfolio
Lower EBIT Margin than peer group
High valuation
Very low/no dividend yield expected
Neptune Wellness Solutions Inc
Start price
Target price
Perf. (%)
€60.55
16.11.20
16.11.20
€105.00
16.11.21
16.11.21
-10.40%
28.11.20
28.11.20
Could be worthwhile Investment >10% per year
Good rating
Differentiated customer and product portfolio
Risky balance sheet
Arbutus Biopharma Corp.
Start price
Target price
Perf. (%)
€3.45
16.11.20
16.11.20
-
16.11.21
16.11.21
-14.81%
17.11.21
17.11.21
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
Stable Large shareholder and/or long term investor
Future proof or reliable business model
Nymox Pharmaceutical Corp.
Start price
Target price
Perf. (%)
€1.66
13.11.20
13.11.20
-
13.11.21
13.11.21
-33.13%
15.07.21
15.07.21
Promis Neurosciences Inc.
Start price
Target price
Perf. (%)
€4.04
13.11.20
13.11.20
-
13.11.21
13.11.21
104.01%
15.07.21
15.07.21
Neptune Wellness Solutions Inc
Start price
Target price
Perf. (%)
€54.95
13.11.20
13.11.20
-
13.11.21
13.11.21
-40.00%
15.07.21
15.07.21
Neptune Wellness Solutions Inc
Start price
Target price
Perf. (%)
€57.75
02.11.20
02.11.20
-
04.11.21
04.11.21
-4.85%
13.11.20
13.11.20
Xenon Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€8.25
29.10.20
29.10.20
-
04.11.21
04.11.21
79.39%
15.07.21
15.07.21
Promis Neurosciences Inc.
Start price
Target price
Perf. (%)
€4.14
29.10.20
29.10.20
-
04.11.21
04.11.21
-2.32%
13.11.20
13.11.20
Arbutus Biopharma Corp.
Start price
Target price
Perf. (%)
€2.53
28.10.20
28.10.20
€2.10
04.11.21
04.11.21
8.70%
19.11.20
19.11.20
Differentiated customer and product portfolio
Lower EBIT Margin than peer group
High valuation
Very low/no dividend yield expected